Cancer cell invasion and metastasis require the concerted action of several proteases that degrade extracellular matrix proteins and basement membranes. Recent reports suggest the plasminogen activator system plays a critical role in pancreatic cancer biology. In the present study, we determined the contribution of the plasminogen activator system to pancreatic cancer cell invasion in vitro. Moreover, the effect of peroxisome proliferatoractivated receptor (PPAR)-; ligands, which are currently in clinical use as antidiabetic drugs and interestingly seem to display antitumor activities, on pancreatic cancer cell invasion and the plasminogen activator system was assessed. Expression of components of the plasminogen activator system [i.e., urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor-1, and uPA receptor] was detected in six human pancreatic cancer cell lines. Inhibition of urokinase activity by specific synthetic compounds reduced baseline pancreatic cancer cell invasion. The PPAR-; ligands 15-deoxy-# 12,14 -prostaglandin J 2 and ciglitazone also attenuated pancreatic cancer cell invasion. This effect was abrogated by dominant-negative PPAR-; receptors and pharmacologic PPAR-; inhibitors. Moreover, activation of PPAR-; by ligands increased plasminogen activator inhibitor-1 and decreased uPA levels in pancreatic cancer cells, and this was accompanied by a reduction in total urokinase activity. The present study shows that the plasminogen activator system plays an integral role in pancreatic cancer cell invasion in vitro. Activation of the nuclear receptor PPAR-; by ligands reduced pancreatic cancer cell invasion, which was largely mediated by modulation of the plasminogen activator system. These findings further underscore the potential role of PPAR-; ligands as therapeutic agents in pancreatic cancer. (Mol Cancer Res 2006;4(3):159-67) 
Introduction
Tumor progression and metastasis involve degradation of extracellular matrix, a process that is governed by an intricate balance of proteases, their activators, and their inhibitors, allowing malignant cells to infiltrate adjacent structures and to gain access to lymph and blood vessels. These proteases can be categorized broadly into three families: matrix metalloproteinases, serine proteinases, and cysteine proteinases. Human pancreatic cancer, a highly aggressive tumor, is characterized by up-regulation of several proteases from each family. Recent studies using microarray technology indicate an important role of the serine proteinase urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in pancreatic cancer (1, 2) . In addition, concomitant overexpression of uPA and uPAR in patients with pancreatic cancer was associated with a shorter postoperative survival (3) . uPA, a 53-kDa serine protease, is secreted by tumor cells in an enzymatically inactive single-chain form (sc-uPA or pro-uPA) and binds to uPAR (CD87), a glycoprotein linked to the cell membrane by a glycosyl phosphatidylinositol anchor (4) . Although the physiologic activator is unknown, different proteases, including plasmin and cathepsin B, have been shown to activate uPA in vitro (5) . The enzymatically active two-chain uPA catalyzes the conversion of plasminogen to plasmin, another serine protease with broad substrate specificity. The enzymatic activity of uPA is counterbalanced by plasminogen activator inhibitor (PAI)-1 and PAI-2, which belong to the serine protease inhibitor family of protease inhibitors (6) . The 43-kDa PAI-1 is thought to be the primary physiologic inhibitor of uPA. It reacts rapidly with uPA, forming a stable complex with a 1:1 stoichiometry (6) . In addition, PAI-1 binds to the extracellular matrix protein vitronectin, thereby potentially modulating cell adhesion and migration, and induces the internalization and degradation of uPAR-bound uPA (5) .
Peroxisome proliferator-activated receptors (PPAR) are ligand-activated transcription factors, which belong to the nuclear hormone receptor superfamily (7) . On ligand binding, PPARs form functional heterodimers with retinoid X receptors. The PPAR/retinoid X receptor complex binds to specific peroxisome proliferator response elements (PPRE) controlling the expression of a large array of genes (8) . Three major subtypes have been described (PPAR-a, PPAR-h/y, and PPAR-g), which are linked to hyperlipidemia, type II diabetes, adipocyte differentiation, and atherosclerosis (9) . More recently, a possible role of PPAR-g in human malignancies has been implicated (10) . PPAR-g is overexpressed in various tumors, including pancreatic cancers, and affects many facets of cancer biology, including differentiation, proliferation, invasion, and angiogenesis (10) . In pancreatic cancer cells, activation of PPAR-g induces cell cycle arrest with terminal differentiation and apoptosis (11) (12) (13) and decreases invasion (14, 15) . PPAR ligands include the fibrate class of hypolipidemic drugs, the thiazolidinedione class of antidiabetic drugs, and derivatives of fatty acid metabolism (16) . Thiazolidinediones are currently in clinical use in the treatment of type II diabetes and have been shown to increase sensitivity of insulin receptors in patients with type II diabetes and to attenuate atherosclerosis by improving endothelial cell function and inhibiting inflammation (17) . Regulation of the plasminogen system by PPAR-g ligands may contribute to the antiatherogenic properties by restoring the fibrinolytic activity of plasmin (17) . In this context, PPAR-g ligands have been shown to modulate PAI-1 secretion by endothelial cells and adipocytes (18) (19) (20) .
In this study, we describe the importance of the plasminogen activator system for the invasion of pancreatic cancer cells. We found that PPAR-g ligands decreased pancreatic cancer cell invasion by specific PPAR-g-mediated regulation of uPA and PAI-1. To our knowledge, this is the first comprehensive report of a regulatory function of PPAR-g on both uPA and PAI-1 in human cancers.
Results

Inhibitors of uPA Decrease Baseline Pancreatic Cancer Cell Invasion
The expression of various components of the urokinase activator system by pancreatic cancer cells was first evaluated using semiquantitative PCR. Using specific intron-spanning primers to rule out amplification of genomic DNA, uPA, PAI-1, and uPAR mRNA transcripts were detected in six human pancreatic cancer cell lines (Fig. 1A) . Primers for the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were added together with the uPA, PAI-1, and uPAR primers to the same reaction tube for semiquantitative analysis. ELISA analysis showed that MIA PaCa-2 and PANC-1 cells had the highest concentration of uPA and PAI-1 protein in the culture medium, whereas PAI-1 levels in Capan-2 cells were virtually undetectable (Fig. 1B and C) . Notably, PAI-1 levels were generally 5 to 10 times higher than uPA levels. Using a chromogenic substrate for uPA, cell culture medium of Capan-2 cells showed the highest urokinase activity (Fig. 1D ). To determine whether the plasminogen activator system contributes to baseline invasion of pancreatic cancer cells, we used two small-molecule uPA inhibitors, WX-582 and WX-UK1. WX-UK1, a derivative of 3-aminophenylalanine, has been shown to selectively inhibit tumor-specific proteases, including uPA, and to reduce growth and metastasis in a rat breast cancer model (21) . WX-582, a phenylguanidine derivative, is a novel, highly selective, and active uPA inhibitor. Both inhibitors dosedependently decreased urokinase activity in Capan-2 conditioned culture medium, with WX-582 being more effective at lower concentrations (IC 50 < 1 Amol/L; Fig. 2A) . In a Matrigel FIGURE 1. Expression of components of the plasminogen activator system in pancreatic cancer cells. A. Expression of uPA, PAI-1, and uPAR in six human pancreatic cancer cell lines was determined by reverse transcription-PCR using intron-spanning primers and GAPDH as a housekeeping gene in the same reaction tube. Amplicons were confirmed by sequencing. B and C. Protein levels of uPA (B) and PAI-1 (C) in conditioned cell culture medium were measured by specific ELISA kits and normalized to cell number and incubation time. Columns, mean of at least three independent experiments; bars, SD. D. Total urokinase activity in conditioned cell culture medium was determined by a chromogenic assay using a specific uPA substrate. Absorbance of the free chromophore was measured at k 405 . Columns, mean of at least three independent experiments; bars, SD.
invasion assay, both inhibitors at 1 and 10 Amol/L significantly decreased invasion of MIA PaCa-2, PANC-1, and Capan-2 cells (Fig. 2B) . WX-582 was slightly more effective in reducing invasion than WX-UK1, which corresponded to the stronger inhibitory effect of WX-582 on urokinase activity at these concentrations. Moreover, the anti-invasive effect of both uPA inhibitors was significantly more pronounced in Capan-2 cells, which displayed the highest urokinase activity in vitro.
PPAR-c Ligands Reduce Pancreatic Cancer Cell Invasion
We have reported previously that PPAR-g ligands decrease pancreatic cancer cell growth by induction of apoptosis (11) . In addition, there is accumulating evidence that PPAR-g ligands also affect cancer cell invasion and metastasis (22) . Because some of the antiatherogenic properties of PPAR-g ligands in patients with type II diabetes may be related to modulation of plasminogen system (17), we investigated the potential effect of PPAR-g ligands on pancreatic cancer cell invasion and assessed the contribution of the plasminogen activator system to this process. Two established PPAR-g ligands, 15-deoxy-D 12,14 -prostaglandin J 2 (15-PGJ 2 ), a naturally occurring, nonenzymatically formed dehydration product of prostaglandin D 2 , and ciglitazone, a thiazolidinedione, dosedependently decreased invasion of MIA PaCa-2, PANC-1, and Capan-2 cells ( Fig. 2A-C) . At a concentration of 10 Amol/L, both ligands decreased invasion of all three cell lines by f70% to 80%. Adding the uPA inhibitors WX-582 and WK-UK1 (at concentrations that inhibited urokinase activity by 70-90%) to 15-PGJ 2 and ciglitazone had no additional effect on pancreatic cancer cell invasion. The anti-invasive effects of both PPAR-g ligands at 10 Amol/L with or without the uPA inhibitors, however, were slightly more pronounced than of the uPA inhibitors alone ( Fig. 2C and D) .
PPAR-c Ligands Decrease uPA and Increase PAI-1 Levels in Pancreatic Cancer Cells
Having shown that PPAR-g ligands and uPA inhibitors reduced pancreatic cancer cell invasion in vitro, the effect of PPAR-g ligands on expression and activity of the plasminogen activator system was assessed. 15-PGJ 2 and ciglitazone dose-dependently decreased uPA protein levels in the culture medium of MIA PaCa-2, PANC-1, and Capan-2 cells (Fig. 3A) . Conversely, both ligands dose-dependently increased PAI-1 levels in all three cell lines (Fig. 3B ). Significant changes were seen at concentrations as low as 1 Amol/L of both ligands. Because the uPA and PAI-1 ELISA kits detect both inactive and active forms of uPA and PAI-1 together with uPA/PAI-1 complexes, the PPAR-g ligand-induced changes in uPA and PAI-1 protein levels in the culture medium reflect changes in total protein levels rather than fluctuations between proform and mature form of both proteins. In addition, 15-PGJ 2 and ciglitazone had no effect on uPAR expression (data not shown). PPAR-g ligand-induced changes in uPA and PAI-1 levels correlated with a reduced overall urokinase activity in MIA PaCa-2, PANC-1, and Capan-2 cells (Fig. 3C ). To determine whether the effects of PPAR-g ligands on uPA and PAI-1 protein expression are regulated on the transcriptional levels, RNase protection assays were done. Multiplex RNase protection assay with GAPDH as an internal control showed a dosedependent decrease in uPA transcripts in MIA PaCa-2 cells treated with 15-PGJ 2 (Fig. 3D) . In contrast, 15-PGJ 2 dosedependently increased PAI-1 mRNA levels (Fig. 3D) .
Anti-invasive Effects of 15-PGJ 2 Are Mediated by PPAR-c
There is increasing evidence that some effects of PPAR-g ligands are mediated by PPAR-g-independent mechanisms (23) . To determine whether the effects of 15-PGJ 2 on pancreatic cancer cell invasion were indeed mediated by activation of PPAR-g, a dominant-negative PPAR-g receptor and a pharmacologic PPAR-g inhibitor were assessed. Two highly conserved hydrophobic and charged amino acid residues (Leu 468 and Glu 471 ) in helix 12 of the ligand-binding domain of PPAR-g were mutated into alanine. This compound PPAR-g mutant (LEA) retains ligand and DNA binding but exhibits markedly PANC-1, and Capan-2 cells were incubated with 15-PGJ 2 (top ) or ciglitazone (bottom ) for 24 hours in serum-free medium, and uPA (A) and PAI-1 (B) levels in the culture medium were determined by ELISA and normalized to cell number. Columns, mean of three independent experiments; bars, SD. *,
cancer cells were incubated with 15-PGJ 2 for 24 hours in serum-free medium and total urokinase activity in the conditioned cell culture medium was determined by a chromogenic assay using a specific uPA substrate. Absorbance of the free chromophore was measured at k 405 . Columns, mean percentage compared with control of at least three independent experiments; bars, SD. *, P < 0.01 versus 15-PGJ 2 (0 Amol/L). D. reduced transactivation due to impaired coactivator recruitment (24) . The dominant-negative PPAR-g mutant was subcloned into a recombinant type 5 adenovirus. The pharmacologic PPAR-g inhibitor GW9662 at 10 Amol/L and the dominantnegative PPAR-g almost completely reversed the 15-PGJ 2 -induced decrease in MIA PaCa-2 cell invasion, whereas the control virus had no effect (Fig. 4A) . In the absence of PPAR-g ligands, the dominant-negative PPAR-g receptor slightly reduced baseline cell invasion, which was not different compared with control virus-transfected cells (data not shown). The inhibitory effect of the dominant-negative PPAR-g on the 15-PGJ 2 -induced decrease in MIA PaCa-2 cell invasion was significantly attenuated by adding the specific uPA inhibitor WX-582 (Fig. 4B ). WX-582 had no additional effect in control virus-infected cells. To confirm whether dominant-negative PPAR-g and GW9662 decreased PPAR-g transcriptional activity, reporter assays were done. 15-PGJ 2 at 10 Amol/L markedly increased PPAR-g activity, which was almost completely inhibited by the double-mutant PPAR-g and the pharmacologic inhibitor GW9662 (Fig. 4C) . When compared with control viruses, infection of MIA PaCa-2 cells with PPARg-encoding adenoviruses lead to a robust overexpression of PPAR-g (Fig. 4D) . In addition, the dominant-negative PPAR-g completely blocked the effects of 15-PGJ 2 on uPA and PAI-1 levels in the culture medium of MIA PaCa-2 cells, whereas the control virus had no effect (Fig. 4E and F) .
Discussion
There is growing evidence that the plasminogen system represents a critical regulatory system in pancreatic cancer invasion. Components of the plasminogen system, including plasminogen activators (particularly the urokinase-type), uPAR, and PAI, are overexpressed in human pancreatic cancers and correlate to poor survival (3, (25) (26) (27) . In our study, uPA, uPAR, and PAI-1 expression was detected in six human pancreatic cancer cell lines. Interestingly, although well-differentiated Capan-2 cells secreted only moderate amounts of uPA into the culture medium, the virtual absence of secreted PAI-1 translated into the highest overall enzymatic uPA activity in this cell line. The contribution of the serine protease uPA to baseline pancreatic cancer cell invasion was assessed using two smallmolecule inhibitors of uPA. At concentrations of both inhibitors that nearly abolished uPA activity in conditioned cell culture medium, invasion of three pancreatic cancer cell lines was reduced by 60% to 75%, indicating a pivotal role of uPA in baseline pancreatic cancer cell invasion in vitro. This is supported by the recent finding that targeting the uPAR inhibited the invasion and metastatic spread in an orthotopic mouse model of pancreatic cancer (28) .
We have shown previously that ligands of the nuclear receptor PPAR-g attenuated pancreatic cancer cell growth in vitro by induction of apoptosis (11) . In the present study, the endogenous and exogenous PPAR-g ligands 15-PGJ 2 and ciglitazone, respectively, dose-dependently inhibited pancreatic cancer cell invasion, further supporting the notion of PPAR-g ligands as being potentially therapeutic agents in pancreatic cancer. There is now accumulating evidence that PPAR-g ligands possess potent anti-invasive properties in human cancers (29) (30) (31) . Our findings that PPAR-g ligands decreased uPA and increased PAI-1 levels in pancreatic cancer cells, thereby substantially reducing overall urokinase activity, strongly suggested that the anti-invasive properties of PPAR-g ligands were mediated by modulating the plasminogen activator system. However, both PPAR-g ligands reduced cell invasion to a slightly greater extent than both uPA inhibitors. The combination of uPA inhibitors and PPAR-g ligands had no additional anti-invasive effect compared with the PPAR-g ligands alone. These findings suggest that PPAR-g ligands decrease pancreatic cancer cell invasion largely by reducing urokinase activity but also affect other protease systems. Members of the matrix metalloproteinase family are candidate proteases, which have been shown to be regulated by PPAR-g agonists (32) (33) (34) .
Our data suggest that PPAR-g ligands regulate uPA and PAI-1 levels on the transcriptional level. The precise mechanisms by which PPAR-g ligands modulate PAI-1 and uPA transcription remain to be defined. The PAI-1 promoter, which lacks a consensus PPAR response element (PPRE), contains cis-acting elements for CAAT/enhancer-binding protein and signal transducers and activators of transcription (35, 36) . It is conceivable that activation of PPAR-g induces the expression of other transcription factors, which in turn regulate PAI-1 gene transcription (37, 38) . This hypothesis is supported by a recent study (39) showing slow kinetics of PAI-1 mRNA induction with pioglitazone (maximal induction observed after 72 hours), which is consistent with de novo protein synthesis (e.g., for new transcription factors). In our study, however, we found a significant increase in PAI-1 mRNA and protein within 24 hours of incubation with 15-PGJ 2 and ciglitazone, which is in accordance to a study by Xin et al. showing increased PAI-1 mRNA expression after 24-hour treatment of human umbilical vein endothelial cells with 15-PGJ 2 (40) . This suggests rather a direct regulatory effect of PPAR-g on PAI-1 gene transcription. A putative, atypical PPRE (TCCCCCATGCCCT) can be found in the 5V flanking region of the PAI-1 gene, which shares great similarity to another published nonconsensus PPRE (TGCCCTTTCCCCC) in the lipoprotein lipase promoter (41) . However, whether PPAR-g binds to this putative PPRE, thereby regulating PAI-1 gene expression, or the effect of PPAR-g is mediated by other transcription factors remains to be determined. In addition to changes in PAI-1 expression, we found that 15-PGJ 2 and ciglitazone dose-dependently decreased uPA mRNA levels. The nuclear factor-nB, which is constitutively active in pancreatic cancer cells and functions as a survival factor, seems to regulate uPA expression in pancreatic cancers (42) . Furthermore, the transforming growth factor-h, which is overexpressed in pancreatic cancers, has been shown to increase uPA levels in pancreatic cancer cells (43, 44) . Recent studies suggest that PPAR-g can inhibit gene transcription by transrepression of other transcription factors (45) . The observations that PPARs directly interact with nuclear factor-nB subunits and transforming growth factor-h/Smad signaling support the hypothesis that PPAR-g ligands may regulate uPA expression in pancreatic cancer cells by transrepression of nuclear factor-nB and/or transforming growth factor-h signaling (46, 47) .
There is now substantial evidence that PPAR-g ligands exert some of their biological effects by PPAR-g-independent mechanisms (23) . Using a dominant-negative PPAR-g mutant and a pharmacologic inhibitor, our data showed that the antiinvasive properties of 15-PGJ 2 were indeed mediated by PPAR-g. Interestingly, the inhibitory effect of the dominant-negative mutant on the 15-PGJ 2 -induced decrease in pancreatic cancer cell invasion was reversed by the specific uPA inhibitor, further indicating that PPAR-g regulates pancreatic cancer cell invasion by modulation of the urokinase activator system. The efficacy of both genetic and pharmacologic approaches to inhibit PPAR-g transcriptional activity was confirmed by reporter assays. These results are in contrast to a recent study describing that thiazolidinediones inhibit pancreatic cancer cell invasion by PPAR-g-independent mechanisms (48) . In this study, the thiazolidinediones rosiglitazone and pioglitazone reduced pancreatic cancer cell invasion, which was not attenuated by the synthetic PPAR-g inhibitors biphenol A diglycidyl ether and GW9662. The exact reasons for this discrepancy are unclear, but the use of different PPAR-g ligands and differences in the invasion assay protocol may account for that observation. In contrast to our study, the PPAR-g ligands and inhibitors were added simultaneously to the cells and invasion was determined after only 6 hours. It is conceivable although speculative that a putative effect of the inhibitors may have been detectable after 24 hours. Furthermore, the authors did not determine whether both inhibitors actually blocked PPAR-g transcriptional activity. Our study, however, is in accordance to a recent report in which GW9662 inhibited the rosiglitazone-induced reduction in pancreatic cancer invasion (14) .
In summary, we found that the urokinase activator system plays a major role in baseline invasion of pancreatic cancer cells. Ligands of the nuclear receptor PPAR-g attenuated pancreatic cancer cell invasion, thereby confirming previous studies. The anti-invasive properties of PPAR-g ligands were largely mediated by specific PPAR-g-dependent changes in the plasminogen activator system. Our study showed for the first time a regulatory role of PPAR-g in uPA and PAI-1 expression in pancreatic cancer, thereby attenuating cell invasion. These findings further support the notion of PPAR-g ligands as being novel therapeutic agents in pancreatic cancer.
Materials and Methods
Reagents
The PPAR-g ligands 15-PGJ 2 and ciglitazone, the polyclonal PPAR-g antibody, and the pharmacologic PPAR-g inhibitor GW9662 were purchased from Cayman Chemical 
Cell Culture
The human pancreatic cancer cell lines AsPC-1 (well to poorly differentiated), BxPC-3 (well to poorly differentiated), Capan-2 (well differentiated), HPAF-II (moderately differentiated), MIA PaCa-2 (undifferentiated), and PANC-1 (poorly differentiated) were obtained from the American Type Culture Collection (Rockville, MD) and cultured as described previously (50).
Reverse Transcription-PCR Amplification of uPA, PAI-1, and uPAR
Total RNA of human pancreatic cancer cell lines was reverse transcribed with avian myeloblastosis virus reverse transcriptase (Roche Diagnostics Corp., Indianapolis, IN). Intronspanning PCR primers for human uPA, PAI-1, uPAR, and GAPDH (Genbank accession nos. XM_055906, X_04429, NM_002659, and NM_002046, respectively) have been designed as follows: uPA fragment forward (5V-GCCTTGTGA-AGATCCGTTCCAAGGAGGGC-3V; 858-887), uPA fragment reverse (5V-CGCATTTCTGTGGACTGCC-3V; 1,316-1,287), PAI-1 fragment forward (5V-GCTGAATTCCTGGAGCTCAG-3V; 49-68), PAI-1 fragment reverse (5V-CTGCGCCACCTGCT-GAAACA-3V; 270-251), uPAR fragment forward (5V-CGG-TGCATGCAGTGTAAGAC-3V; 496-515), uPAR fragment reverse (5V-CAGGAAGTGGAAGGTGTCGT-3V; 996-977), GAPDH fragment forward (5V-AAGTACCGCTGAA-3V; 730-749), and GAPDH fragment reverse (5V-CCCCTCTTCAAG-GGGTCTAC-3V; 1,224-1,205). PCR amplifications of uPA, PAI-1, and uPAR were carried out together with GAPDH in the same reaction tube for 30 cycles as follows: 94jC for 1 minute, 60jC (uPA and uPAR) or 50jC (PAI-1) for 30 seconds, and 72jC for 1 minute. Amplicons were separated on a 1% agarose gel.
PAI-1 and uPA Protein Levels
Cells were incubated with incremental concentrations of 15-PGJ 2 or ciglitazone for 24 hours. PAI-1 and uPA concentrations in the cell culture supernatant were measured using the Immubind Tissue PAI-1 ELISA kit and Immubind uPA ELISA kit (American Diagnostica, Inc., Greenwich, CT) according to the manufacturer's recommendations. The Immubind Tissue PAI-1 ELISA kit detects inactive and active forms of PAI-1 and PAI-1 complexes and is insensitive to PAI-2. The Immubind uPA ELISA kit recognizes single-chain uPA (pro-uPA) and high molecular weight uPA forms (receptor-bound uPA and uPA complexed with PAI-1 and PAI-2). The lower detection limit of the PAI-1 and uPA assay is 50 pg PAI-1/mL and 10 pg uPA/mL, respectively, according to the manufacturer.
uPA Activity Assay
Total uPA activity in cell culture supernatants was determined by the uPA Activity Assay kit (Chemicon International, Temecula, CA) using a chromogenic substrate. uPA activity was determined by measuring the increase in absorbance of the free chromophore pNA at k 405 .
Preparation of Riboprobes
Templates for riboprobes were generated using the following primers for uPA, PAI-1, and GAPDH (Genbank accession nos. XM_044354.6, M16006, and NM_002046, respectively): uPA fragment forward (5V-TCACCACCAAAATGCTGTGT-3V; 1,093-1,112), uPA fragment reverse (5V-AGGCCATTCTCTT-CCTTGGT-3V; 1,315-1,296), PAI-1 fragment forward (5V-CTCTCTCTGCCCTCACCAAC-3V; 881-900), PAI-1 fragment reverse (5V-GGGAGAGGCTCTTGGTCTG-3V; 1,092-1,073), GAPDH fragment forward (5V-AAGGTCATGA-GCTGAA-3V; 730-749), and GAPDH fragment reverse (5V-CCCTCTCAAGGGTTAC-3V; 1,224-1,205). The size of the riboprobes was designed to allow for simultaneous multiplex analysis of samples. A T7 RNA polymerase promoter was ligated to the cDNA using the Lig'nScribe kit (Ambion, Inc., Austin, TX). Antisense radiolabeled riboprobes were generated using an in vitro transcription kit (MAXIscript; Ambion) with 1 Ag uPA, PAI-1, or GAPDH fragment, T7 RNA polymerase, and [a-
32 P]UTP. Probes were run on a 5% acrylamide/8 mol/L urea gel and full-length riboprobes were gel purified.
RNase Protection Assay
Cells were incubated with 15-PGJ 2 (0-10 Amol/L) for 6 hours. Total RNA was reverse transcribed with avian myeloblastosis virus (Roche). Using the RNase Protection Assay III (Ambion), 10 Ag total mRNA was hybridized with 80,000 cpm uPA and PAI-1 and 40,000 cpm GAPDH radiolabeled antisense riboprobe, which protected 275-, 264-, and 547-bp fragments, respectively. Free probe and singlestranded mRNA were digested with RNase A and T1. Hybridized samples were precipitated and electrophoresed on a 5% acrylamide/8 mol/L urea gel. The gel was exposed to Kodak BioMax MS film (Eastman Kodak Co., Rochester, NY). Yeast RNA incubated with uPA, PAI-1, or GAPDH riboprobes with or without RNase treatment served as RNase efficiency and full-length riboprobe integrity controls.
Dominant-Negative PPAR-c
A dominant-negative form of PPAR-g was constructed by mutating the Leu 468 and Glu 471 of the full-length PPAR-g1 into Ala using the QuickChange Site-Directed Mutagenesis kit (Clontech, Palo Alto, CA). Mutations at these sites create a dominant-negative form of PPAR-g (24) . The dominantnegative PPAR-g was subcloned into recombinant type 5 adenovirus using the Adeno-X Expression System (Clontech) and designated as Adx-D/N-PPAR-g. Recombinant type 5 adenovirus expressing the LacZ gene was generated similarly and used as a control vector (Adx-LacZ). Cells were infected with 75 plaque forming units/cell in DMEM containing 0.4% fetal bovine serum for 24 hours.
